专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010132867A1 VACCINE IMMUNOTHERAPY 审中-公开
标题翻译：疫苗免疫
公开(公告)号：WO2010132867A1
公开(公告)日：2010-11-18
申请号：PCT/US2010/035060
申请日：2010-05-17
申请人： IRX THERAPEUTICS, INC. , HADDEN, John W. , SIGNORELLI, Kathy , EGAN, James , NAYLOR, Paul
发明人： HADDEN, John W. , SIGNORELLI, Kathy , EGAN, James , NAYLOR, Paul
IPC分类号： A61K45/00 , A61K38/21
CPC分类号： A61K39/39 , A61K38/164 , A61K38/177 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/6081 , A61K2300/00
摘要： A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
摘要翻译：一种用于治疗癌症的组合物，包括具有细胞因子IL-1，IL-2，IL-6，IL-8，TNF-α和IFN-γ的主要细胞衍生生物的协同量，以及具有至少一种抗原。一种组合物，其包含与至少一种佐剂组合的协同量的原代细胞来源的生物制剂。通过施用组合物治疗癌症的方法。逆转免疫抑制和获得癌症免疫力的方法。产生对外源性抗原的免疫应答的方法。一种通过将主要细胞来源的生物与至少一种佐剂组合施用来增强患者的免疫应答的方法，以及通过所述原代细胞衍生的生物学和佐剂的协同相互作用增强患者的免疫应答。增加免疫系统功能的方法。

2. 发明申请

WO2009146392A1 MECHANISM OF ACTION OF PRIMARY CELL DERIVED BIOLOGIC 审中-公开
标题翻译：主要细胞衍生生物学行为机制
公开(公告)号：WO2009146392A1
公开(公告)日：2009-12-03
申请号：PCT/US2009/045550
申请日：2009-05-29
申请人： IRX THERAPEUTICS, INC. , HADDEN, John, W.
发明人： HADDEN, John, W.
IPC分类号： A61K39/395
CPC分类号： A61K39/0011 , A61K31/675 , A61K36/00 , A61K45/06 , A61K2039/545 , A61K2300/00
摘要： A method of treating an immune target that is suppressing the immune system and restoring the immune system, including the steps of administering an effective amount of a primary cell derived biologic, modifying populations of B and T cells in blood, activating regional lymph nodes, infiltrating an area adjacent to an immune target with T helper and B cells, infiltrating the immune traget with T killer cells and macrophages, and treating the immune target and restoring the immune system. A method of inducing immunization in a patient. A method of destroying a tumor. A method of predicting a favorable treatment outcome to cancer treatment. A method of immune prophylaxis. A method of immune restoration. A method of treating a tumor. A method of preventing tumor escape.
摘要翻译：一种治疗免疫系统的免疫系统和恢复免疫系统的方法，包括以下步骤：施用有效量的原代细胞来源的生物学，修饰血液中B和T细胞的群体，激活区域性淋巴结，浸润与T辅助细胞和B细胞的免疫靶标相邻的区域，用T细胞和巨噬细胞浸润免疫Traget，以及治疗免疫靶标并恢复免疫系统。一种诱导患者免疫的方法。破坏肿瘤的方法。预测癌症治疗有利治疗结果的方法。免疫预防的方法。免疫恢复的方法。一种治疗肿瘤的方法。一种防止肿瘤逃逸的方法。

3. 发明申请

WO2007136910A3 EIMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
标题翻译：免疫抑制患者的电子护理
公开(公告)号：WO2007136910A3
公开(公告)日：2008-12-04
申请号：PCT/US2007063633
申请日：2007-03-09
申请人： IRX THERAPEUTICS INC , HADDEN JOHN W , NAYLOR PAUL
发明人： HADDEN JOHN W , NAYLOR PAUL
IPC分类号： A61K48/00
CPC分类号： A61K38/193 , A61K31/192 , A61K31/405 , A61K31/675 , A61K38/191 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
摘要翻译：本发明提供了一种天然细胞因子混合物（NCM）的组合物，其用于治疗以T淋巴细胞减少为特征的细胞免疫缺陷，一种或多种树突细胞功能缺陷，例如与淋巴结窦组织细胞增多症有关的功能缺陷，和/或一种或多种单核细胞功能缺陷如与NCM的阴性皮肤试验相关的那些。本发明包括使用本发明的NCM治疗这些细胞免疫缺陷的方法。组合物和方法可用于治疗与细胞免疫缺陷如癌症相关的疾病。还提供了用于逆转肿瘤诱导的免疫抑制的组合物和方法，包括化学抑制剂和非甾体抗炎药（NSAID）。本发明还提供了一种诊断性皮肤试验，其包括用于预测癌症患者的治疗结果的NCM。

4. 发明申请

WO2009070639A1 METHOD OF INCREASING IMMUNOLOGICAL EFFECT 审中-公开
标题翻译：增加免疫力的方法
公开(公告)号：WO2009070639A1
公开(公告)日：2009-06-04
申请号：PCT/US2008/084789
申请日：2008-11-26
申请人： IRX THERAPEUTICS, INC. , SIGNORELLI, Kathy, L. , CZYSTOWSKA, Margareta , EGAN, James, E. , BRANDWEIN, Harvey , WHITESIDE, Theresa, L. , HADDEN, John, W.
发明人： SIGNORELLI, Kathy, L. , CZYSTOWSKA, Margareta , EGAN, James, E. , BRANDWEIN, Harvey , WHITESIDE, Theresa, L. , HADDEN, John, W.
IPC分类号： A61K45/00
CPC分类号： A61K45/06 , A61K31/4439 , A61K33/00 , Y10S514/885 , A61K2300/00
摘要： A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.
摘要翻译：通过向患者施用有效量的原代细胞来源的生物学，诱导免疫产生，阻断免疫破坏和增加患者的免疫学作用，增加患者免疫学效果的方法。治疗免疫靶标，治疗肿瘤，免疫预防和预防肿瘤逃逸的方法。

5. 发明申请

WO2008101154A3 IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
标题翻译：免疫抑制患者的免疫治疗
公开(公告)号：WO2008101154A3
公开(公告)日：2008-12-24
申请号：PCT/US2008054070
申请日：2008-02-15
申请人： IRX THERAPEUTICS INC , HADDEN JOHN W
发明人： HADDEN JOHN W
IPC分类号： G01N33/53 , G01N33/567
CPC分类号： A61K49/0006 , G01N33/5091 , G01N33/574 , G01N2333/715 , G01N2800/00
摘要： A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab- CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3.
摘要翻译：用于预测治疗结果的诊断性皮肤试验，其基本上由有效量的muromonab-CD3的NCM或T淋巴细胞有丝分裂原组成。用于进行基本上由有效量的莫罗单抗-CD3的NCM或T淋巴细胞有丝分裂原组成的皮肤试验的试剂盒。一种对患者进行皮肤测试的方法，基本上由以下步骤组成：向皮肤施用有效量的莫罗单抗-CD3的NCM或T淋巴细胞促分裂素，分析皮肤测试的结果，并预测治疗结果。检测单核细胞或T淋巴细胞功能缺陷的方法，包括向皮肤施用有效量的莫罗单抗-CD3的NCM或T淋巴细胞有丝分裂原，分析皮肤试验结果，以及检测单核细胞或T细胞中至少一种缺陷的步骤淋巴细胞功能。用于指示免疫系统的功能传出或传入肢体的机制，包括诊断性皮肤测试，其包括有效量的莫罗单抗-CD3的NCM或T淋巴细胞有丝分裂原。

6. 发明申请

WO03035004A9 IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION 审中-公开
标题翻译：免疫抑制免疫治疗
公开(公告)号：WO03035004A9
公开(公告)日：2003-12-31
申请号：PCT/US0234361
申请日：2002-10-26
申请人： IMMUNO RX INC , HADDEN JOHN W
发明人： HADDEN JOHN W
IPC分类号： A61K38/00 , A61K31/405 , A61K31/415 , A61K31/4402 , A61K31/664 , A61K38/19 , A61K38/21 , A61K38/22 , A61K39/00 , A61K39/39 , A61P31/04 , A61P35/00 , A61P37/04 , A61P43/00 , C12N5/08 , A61K45/00 , A01N63/00 , A61K47/00
CPC分类号： A61K39/0011 , A61K38/19 , A61K38/2013 , A61K38/2292 , A61K39/39 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2039/55527 , A61K2039/57 , A61K2300/00
摘要： A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin .
摘要翻译：克服免疫抑制的方法包括诱导幼稚T细胞产生和恢复T细胞免疫的步骤。疫苗免疫疗法的方法包括诱导幼稚T细胞产生和在合适的位点将初始T细胞暴露于内源性或外源性抗原的步骤。另外，在区域淋巴结解除免疫接种的方法包括促进区域淋巴结处的未成熟树突细胞的分化和成熟，并使得到的成熟树突细胞呈递加工肽，从而例如使肿瘤肽暴露于 T细胞以获得T细胞的免疫。此外，治疗癌症和其他持续性病变的方法包括以下步骤：将有效量的天然细胞因子混合物作为对内源性或外源性施用的抗原的佐剂给予癌症或其他持续性病变; 优选天然细胞因子混合物与胸腺肽联合给药。

7. 发明申请

WO03035004A2 IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION 审中-公开
标题翻译：免疫反应免疫抑制
公开(公告)号：WO03035004A2
公开(公告)日：2003-05-01
申请号：PCT/US0234361
申请日：2002-10-26
申请人： IMMUNO RX INC , HADDEN JOHN W
发明人： HADDEN JOHN W
IPC分类号： A61K38/00 , A61K31/405 , A61K31/415 , A61K31/4402 , A61K31/664 , A61K38/19 , A61K38/21 , A61K38/22 , A61K39/00 , A61K39/39 , A61P31/04 , A61P35/00 , A61P37/04 , A61P43/00 , C12N5/08 , A61K
CPC分类号： A61K39/0011 , A61K38/19 , A61K38/2013 , A61K38/2292 , A61K39/39 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2039/55527 , A61K2039/57 , A61K2300/00
摘要： A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin .
摘要翻译：克服免疫抑制的方法包括诱导幼稚T细胞的产生和恢复T细胞免疫的步骤。疫苗免疫治疗的方法包括诱导产生初始T细胞并将初始T细胞暴露于适当位点的内源或外源抗原的步骤。另外，在局部淋巴结处解除免疫的方法包括以下步骤：促进区域性淋巴结处的未成熟树突状细胞的分化和成熟，并允许通过产生的成熟树突状细胞呈递加工的肽，从而例如将肿瘤肽暴露于 T细胞获得免疫T细胞。此外，治疗癌症和其它持续性损伤的方法包括以下步骤：将有效量的天然细胞因子混合物作为佐剂施用于内源或外源施用的抗原至癌症或其它持续性损伤; 优选天然细胞因子混合物与胸腺素α组合施用。

8. 发明申请

WO0234119A3 VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
标题翻译：免疫抑制患者的疫苗免疫治疗
公开(公告)号：WO0234119A3
公开(公告)日：2002-07-11
申请号：PCT/US0148039
申请日：2001-10-26
申请人： IMMUNO RX INC , HADDEN JOHN W
发明人： HADDEN JOHN W
IPC分类号： A61K45/00 , A61K31/192 , A61K31/365 , A61K31/405 , A61K31/415 , A61K31/664 , A61K38/00 , A61K38/19 , A61K39/00 , A61K39/39 , A61P31/00 , A61P35/00 , C12N15/19 , C12P21/08 , A01N37/18 , A61K38/21 , C07K14/00
CPC分类号： A61K39/0011 , A61K31/405 , A61K31/496 , A61K31/5383 , A61K31/664 , A61K31/675 , A61K38/191 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/2086 , A61K38/21 , A61K38/217 , A61K39/39 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , A61K2039/55522 , A61K2300/00
摘要： A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
摘要翻译：克服轻度至中度免疫抑制的方法包括诱导幼稚T细胞产生和恢复T细胞免疫的步骤。疫苗免疫疗法的方法包括诱导幼稚T细胞产生和在合适部位将初始T细胞暴露于内源性或外源性抗原的步骤。另外，在区域淋巴结解除免疫接种的方法包括促进区域淋巴结处的未成熟树突细胞的分化和成熟，并使得到的成熟树突细胞呈递加工肽，从而例如使肿瘤肽暴露于 T细胞获得T细胞的免疫。此外，治疗癌症和其他持续性病变的方法包括施用有效量的天然细胞因子混合物作为内源性或外源性施用的抗原对癌症或其他持续性病变的佐剂的步骤。

9. 发明申请

WO2008014220A2 VACCINE IMMUNOTHERAPY 审中-公开
标题翻译：疫苗免疫治疗
公开(公告)号：WO2008014220A2
公开(公告)日：2008-01-31
申请号：PCT/US2007074156
申请日：2007-07-24
申请人： IRX THERAPEUTICS INC , HADDEN JOHN W , SIGNORELLI KATHY , EGAN JAMES
发明人： HADDEN JOHN W , SIGNORELLI KATHY , EGAN JAMES
IPC分类号： A61K38/21 , A61K38/19 , A61K38/20
CPC分类号： A61K39/0011 , A61K38/191 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/217 , A61K2300/00
摘要： The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at (east one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-? (gamma) and TNF-a (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.
摘要翻译：本发明提供了用于治疗癌症或其他抗原生成疾病或损伤的免疫疗法的组合物和方法。根据本发明的一个实施方案，提供了一种组合物，用于引发针对患有产生抗原的疾病或损伤的患者中（至少一种抗原）的免疫应答，所述组合物包含有效量的细胞因子混合物，优选包含IL- 1，IL-2，IL-6，IL-8，IFN-γ（γ）和TNF-αα。细胞因子混合物作为与产生抗原的疾病或病变相关的抗原的佐剂来增强因此还提供了用于利用本发明的细胞因子混合物在患有抗原生成疾病或损伤的患者中引发针对至少一种抗原的免疫应答的方法，所述组合物和方法可用于治疗产生抗原的疾病如癌症，感染性疾病或持续性病变。

10. 发明申请

WO2007136910A2 EIMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
标题翻译：免疫抑制患者的电子护理
公开(公告)号：WO2007136910A2
公开(公告)日：2007-11-29
申请号：PCT/US2007/063633
申请日：2007-03-09
申请人： IRX THERAPEUTICS, INC. , HADDEN, John, W. , NAYLOR, Paul
发明人： HADDEN, John, W. , NAYLOR, Paul
IPC分类号： A61K48/00
CPC分类号： A61K38/193 , A61K31/192 , A61K31/405 , A61K31/675 , A61K38/191 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
摘要翻译：本发明提供了一种天然细胞因子混合物（NCM）的组合物，其用于治疗以T淋巴细胞减少为特征的细胞免疫缺陷，一种或多种树突细胞功能缺陷，例如与淋巴结窦组织细胞增多症有关的功能缺陷，和/或一种或多种单核细胞功能缺陷如与NCM的阴性皮肤试验相关的那些。本发明包括使用本发明的NCM治疗这些细胞免疫缺陷的方法。组合物和方法可用于治疗与细胞免疫缺陷如癌症相关的疾病。还提供了用于逆转肿瘤诱导的免疫抑制的组合物和方法，包括化学抑制剂和非甾体抗炎药（NSAID）。本发明还提供了一种诊断性皮肤试验，其包括用于预测癌症患者的治疗结果的NCM。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式